Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4059 Phase I Study in Patients with Systemic Sclerosis
jRCT2031200315Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tirabrutinib in systemic sclerosis (SSc) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Adverse events, Pharmacokinetics and 1 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
tirabrutinib
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on jRCT2031200315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200315.